UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1420-2
Program Prior Authorization/Notification
Medication Opfolda™ (miglustat)
P&T Approval Date 11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Opfolda (miglustat) is an enzyme stabilizer indicated, in combination with Pombiliti, a hydrolytic
lysosomal glycogen-specific enzyme, for the treatment of adult patients with late-onset Pompe
disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not
improving on their current enzyme replacement therapy (ERT).
2. Coverage Criteriaa:
A. Initial Authorization
1. Opfolda will be approved based on both of the following criteria:
a. Diagnosis of late-onset Pompe disease
-AND-
b. Patient has an active UnitedHealthcare medical benefit prior authorization for
Pombiliti (cipaglucosidase alfa-atga) for the treatment of late-onset Pompe disease
Authorization will be issued for 12 months.
B. Reauthorization
1. Opfolda will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Opfolda plus Pombiliti
-AND-
b. Opfolda continues to be prescribed in combination with Pombiliti
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Opfolda [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2024.
2. Pombiliti [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2024.
Program Prior Authorization/Notification - Opfolda (miglustat)
Change Control
Date Change
11/2023 New program
11/2024 Clarified criteria without change to clinical intent. Updated references.
© 2024 UnitedHealthcare Services Inc.
2